Natera, Inc. ($NTRA) Stock Forecast: Up 5.1% Today

What is Natera, Inc.?

Natera, Inc. is a company specializing in genetic testing and analysis. Recent positive developments include patent victories, new board appointments, and promising scientific results for its Signatera assay.

Why is Natera, Inc. going up?

NTRA stock is up 5.1% on May 6, 2026 17:11

• The bullish movement in Natera's stock today is linked to positive developments such as an "Outperform" rating from William Blair, a patent victory, and promising study results for its Signatera assay.
• The selling of shares by key executives like Sheena Jonathan, John Fesko, and CEO Steven Chapman to cover tax obligations initially raised concerns. However, these pre-arranged transactions, in light of positive news, likely reassured investors about the company's health and future prospects.
• Strategic selling of shares by company insiders under Rule 10b5-1 plans, despite the stock being down year-to-date, may indicate a prudent approach to finance management while maintaining confidence in company performance.
• The combination of positive company developments and strategic insider selling likely fueled the bullish movement in Natera's stock today, demonstrating a blend of financial responsibility and investor confidence in the company's growth trajectory.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Natera co-founder Sheena Jonathan sells $22,059 in common stock

Sheena Jonathan, co-founder of Natera, Inc., sold 107 shares of company stock for $22,059 to cover tax obligations from vested restricted stock units. The transaction was pre-arranged, and she continues to hold significant direct and indirect shares. This news follows other positive developments for Natera, including an "Outperform" rating from William Blair, a patent victory, a new board appointment, and promising scientific results for its Signatera assay.

https://m.investing.com/news/insider-trading-news/natera-cofounder-sheena-jonathan-sells-22059-in-common-stock-93CH-4661630?ampMode=1

Natera president John Fesko sells $59,992 of NTRA shares

Natera's President and Chief Business Officer, John Fesko, sold 291 shares of NTRA stock worth $59,992 on May 1, 2026, to cover tax obligations from restricted stock unit vesting. This transaction, made under a Rule 10b5-1 plan, leaves Fesko with 187,220 shares. The sale occurred ahead of Natera's earnings report, with the stock down 9.74% year-to-date.

https://m.investing.com/news/insider-trading-news/natera-president-john-fesko-sells-59992-of-ntra-shares-93CH-4661621?ampMode=1

Natera CEO Steven Chapman disposes of $185,956 in company stock

Steven Leonard Chapman, CEO of Natera, Inc. (NASDAQ:NTRA), sold 902 shares of company stock for $185,956 on May 1, 2026, to cover tax obligations related to restricted stock unit vesting. Following the sale, Chapman still directly owns 149,867 shares. This transaction follows other recent positive developments for Natera, including a favorable court decision, a new board member, and promising study results for its Signatera assay.

https://m.investing.com/news/insider-trading-news/natera-ceo-steven-chapman-disposes-of-185956-in-company-stock-93CH-4661622?ampMode=1

Natera (NTRA) CEO sells 902 shares in RSU-related tax transaction

Natera CEO Steven Leonard Chapman sold 902 shares of common stock on May 1, 2026, at $206.16 per share. This transaction was conducted to cover tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) and was pre-arranged under a Rule 10b5-1(c) plan. Following the sale, Chapman directly owns 149,867 shares of Natera common stock.

https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-ab4fa782ffd1.html

Natera co-founder Sheena Jonathan sells $22,059 in common stock

Sheena Jonathan, co-founder and director at Natera, Inc. (NASDAQ:NTRA), sold 107 shares of company stock for $22,059 to cover tax obligations from RSU vesting. This transaction was part of a pre-established trading plan, leaving her with significant direct and indirect holdings. The sale occurred amidst other company news, including an "Outperform" rating from William Blair, a patent victory, a new board appointment, and positive scientific results for its Signatera assay.

https://www.investing.com/news/insider-trading-news/natera-cofounder-sheena-jonathan-sells-22059-in-common-stock-93CH-4661630

Trending Today

Novavax Inc. ($NVAX) Stock Forecast: Down 7.6% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 6.1% Today

Ubiquiti ($UI) Stock Forecast: Down 6.8% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Down 3.1% Today

Draftkings Inc ($DKNG) Stock Forecast: Up 5.2% Today

Chemours Company (The) ($CC) Stock Forecast: Down 5.2% Today

Teleflex Incorporated ($TFX) Stock Forecast: Up 7.9% Today

Fortinet Inc. ($FTNT) Stock Forecast: Up 20.9% Today

PTC Inc. ($PTC) Stock Forecast: Up 9.9% Today

Datadog Inc. ($DDOG) Stock Forecast: Up 31.4% Today

Natera, Inc. Price History

01.03.2026 - NTRA Stock was up 5.1%

• The bullish movement in Natera Inc. (NTRA) today could be attributed to the positive results from the Signatera molecular residual disease (MRD) test, particularly in identifying breast cancer patients who may avoid surgery, boosting investor confidence in the company's innovative technology.
• Despite the recent share sell-off by Zevenbergen Capital Investments LLC, the overall market sentiment remains positive, with increased interest from other institutional investors and strong quarterly results beating expectations, supporting the stock's upward momentum.
• The study showcasing the efficacy of Signatera in guiding treatment decisions for older women with early-stage breast cancer likely contributed to the stock's bullish movement, as it highlights the potential market expansion and adoption of Natera's testing solutions.

14.03.2026 - NTRA Stock was up 5.1%

• William Blair started covering Natera with an Outperform rating, emphasizing the company's market position and growth prospects, likely boosting investor confidence.
• A favorable interim futility analysis from Allogene Therapeutics' trial utilizing Natera's CLARITY™ MRD assay showed promising results in large B-cell lymphoma, contributing to the positive sentiment surrounding Natera.
• A court ruling ordering a 30% ongoing royalty for Natera in a patent dispute is a significant win, reinforcing the company's intellectual property rights and potentially increasing future revenue.
• Despite a decrease in price, the increase in trading volume after the legal victory indicates investor interest and optimism in Natera's future financial performance, as they anticipate the impact of these events on upcoming earnings.

14.03.2026 - NTRA Stock was up 5.8%

• Today's positive performance by Natera is linked to William Blair's initiation of coverage on the company, endorsing its strong position in diagnostic markets and growth potential.
• The encouraging interim futility analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial, which uses Natera's CLARITY™ MRD assay, also contributed to the optimistic outlook by demonstrating successful MRD clearance in high-risk patients.
• Furthermore, a recent court ruling that mandates a 30% ongoing royalty payment to Natera in a patent dispute is seen as a significant victory for the company, reinforcing its intellectual property rights and hinting at future financial gains.
• Despite concerns such as potential overvaluation and insider sales, Natera's leadership in the market, early-mover advantage, and progress in cancer research are likely bolstering investor confidence in its future growth opportunities.

17.03.2026 - NTRA Stock was up 5.1%

• Natera (NTRA) reported impressive fourth-quarter results, exceeding earnings and revenue estimates, which likely boosted investor confidence in the company's performance.
• Positive interim futility analysis from Allogene Therapeutics' ALPHA3 trial, utilizing Natera's CLARITY™ MRD assay, showcased the effectiveness of Natera's technology in identifying high-risk patients and potentially preventing relapse in large B-cell lymphoma cases.
• Despite holding a Zacks Rank #4 (Sell) due to estimate revisions, the initiation of coverage by William Blair with an "outperform" recommendation highlighted Natera's strong position in the growing MRD testing market, projecting significant revenue growth potential.
• The mixed share price performance evaluation, indicating undervaluation by DCF model but overvaluation by P/S ratio, suggests varying perspectives on Natera's future valuation and growth prospects, leaving investors with contrasting views on the stock's true value.

23.03.2026 - NTRA Stock was down 5.2%

• The recent bearish movement in Natera's stock could be attributed to:
• Profit-taking by insiders: Co-founder Sheena Jonathan and family trusts selling a significant number of shares could have indicated a lack of confidence in the short-term performance of the stock.
• Overvaluation concerns: Despite the recent price surge, valuation metrics like the Price-to-Sales (P/S) ratio suggesting overvaluation might have led investors to capitalize on their gains.
• Market dynamics: While Natera's stock experienced a downward trend, other companies in the healthcare sector, such as UFP Technologies, Mettler-Toledo, and Viatris, saw substantial gains, potentially diverting investor attention away from Natera.
• Overall market sentiment: The reopening of the Strait of Hormuz resulting in decreased logistics and energy costs may have redirected investor focus to companies directly benefiting from these changes, impacting Natera's stock negatively.

16.03.2026 - NTRA Stock was down 6.8%

• The bearish movement in Natera's stock today could be attributed to the mixed evaluations of its share price performance, with conflicting assessments of undervaluation and overvaluation.
• Despite being positioned to capture a significant share of the $20 billion MRD opportunity and receiving an 'Outperform' rating from William Blair, concerns about overvaluation and insider selling may have dampened investor sentiment.
• The positive interim results from Allogene Therapeutics’ ALPHA3 trial, showcasing the effectiveness of cema-cel in reducing MRD levels in lymphoma patients, could have been overshadowed by broader market uncertainties or profit-taking activities.
• Natera's strong growth potential and competitive advantages in the diagnostics sector may still underpin its long-term prospects, despite short-term market fluctuations.

09.03.2026 - NTRA Stock was down 5.5%

• The bearish movement in Natera's stock today could be attributed to the Executive Chairman exercising stock options and using shares for taxes. This could have potentially raised concerns among investors about insider activities and the company's financial health.
• Despite Citi maintaining a Buy rating and a target price of $300 for Natera, the market might have reacted negatively to the news of insider selling and the challenges the company faces in profitability.
• The positive sentiment around Natera's upside potential and strong growth of Signatera, as mentioned by billionaire investor Stan Druckenmiller and financial analysts, could be overshadowed by short-term concerns leading to the bearish movement in the stock today.
• Investors will likely keep a close eye on Natera's upcoming earnings and financial performance to gauge its future trajectory, balancing the positive long-term outlook with the immediate challenges the company faces.

06.04.2026 - NTRA Stock was up 5.1%

• The bullish movement in Natera's stock today is linked to positive developments such as an "Outperform" rating from William Blair, a patent victory, and promising study results for its Signatera assay.
• The selling of shares by key executives like Sheena Jonathan, John Fesko, and CEO Steven Chapman to cover tax obligations initially raised concerns. However, these pre-arranged transactions, in light of positive news, likely reassured investors about the company's health and future prospects.
• Strategic selling of shares by company insiders under Rule 10b5-1 plans, despite the stock being down year-to-date, may indicate a prudent approach to finance management while maintaining confidence in company performance.
• The combination of positive company developments and strategic insider selling likely fueled the bullish movement in Natera's stock today, demonstrating a blend of financial responsibility and investor confidence in the company's growth trajectory.

30.03.2026 - NTRA Stock was up 5.1%

• The company revealed its first-quarter financial results and held a conference call, potentially boosting investor confidence and fueling the bullish movement.
• Insider selling by the co-founder and CEO, aimed at covering tax obligations, initially raised concerns but a clarified context of these sales being part of a pre-arranged trading plan may have alleviated any negative impact.
• Despite Natera's current lack of profitability, positive court rulings and new analyst coverage could have positively influenced investor sentiment, contributing to the bullish market performance.
• Taken together, positive updates on financial results, structured insider trading activities, and external factors like court decisions and analyst coverage likely played a role in Natera's recent strong bullish trend.

29.03.2026 - NTRA Stock was down 5.0%

• The downward trend in Natera's stock price could be linked to notable insider selling activity by directors such as Roelof Botha, Eric H. Rubin, and Ruth Williams Brinkley. This activity may have sparked concerns among investors regarding the company's future outlook.
• Despite the release of positive information regarding Natera's recent clinical evidence for its Prospera transplant test, which could potentially boost revenue, the overall market sentiment may have been clouded by the insider selling, as well as the company's negative net margins and ROE.
• While the initial increase in M&T Bank Corp's stake could have been viewed as a positive development, investor focus appeared to shift towards the insider selling and the company's financial difficulties, contributing to today's bearish movement in the stock.

10.03.2026 - NTRA Stock was down 5.6%

• The bearish movement in Natera's stock today could be attributed to profit-taking by investors after a recent uptrend following positive legal outcomes.
• The appointment of Director Eric H. Rubin to the insider roster may have raised concerns among investors about potential future decisions or changes within the company.
• Despite the positive rulings in the patent disputes and the increase in royalties, the market may have reacted negatively due to uncertainties surrounding the financial impact on Natera and its competitors.
• The insider activity of the Executive Chairman, Matthew Rabinowitz, exercising stock options and selling shares to cover tax obligations could have also contributed to the downward pressure on the stock price as investors may interpret this as a lack of confidence in the company's future prospects.

10.03.2026 - NTRA Stock was down 7.8%

• The court ruling awarding Natera a 30% royalty on post-injunction revenues from MRD patents against ArcherDx and Invitae was initially seen as a positive development, leading to a slight increase in premarket trading. However, the market may have reacted negatively due to concerns about high cash burn and challenges in clinical trials and reimbursement.
• The addition of director Eric H. Rubin to Natera's insider roster, while providing transparency, did not have a significant impact on the stock movement.
• Despite the favorable court decisions strengthening Natera's intellectual property portfolio, the market may have been influenced by the potential financial implications of the royalty payments on the company's overall performance.
• Analysts revising earnings upwards and the positive influence on stock valuation could indicate long-term growth potential, but the current overvaluation concerns raised in the analysis may have contributed to the bearish market movement.